A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects

• Status: Completed
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine how morbid obesity affects the distribution and metabolism of the drug propofol. The investigators hypothesize that propofol will be distributed and metabolized differently in morbidly obese subjects as compared to normal weight subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Propofol

Criteria

Inclusion Criteria:

• adult age (ages 18-70)

• body mass index greater than 40 or between 20-25

• American Society of Anesthesiologists Class I, II, or III

• undergoing elective surgical procedure requiring general anesthesia

Exclusion Criteria:

• evidence of cardiovascular or pulmonary disease

• kidney or liver dysfunction

• drug allergy to propofol

• history of difficult airway

• on prescribed or over the counter anxiolytics, antipsychotics, or sleeping aids

• unable to speak or understand English